Merck & Co./$MRK

13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX

About Merck & Co.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Ticker

$MRK
Sector

Primary listing

NYSE

Employees

74,000

Merck & Co. Metrics

BasicAdvanced
$210B
12.96
$6.49
0.39
$3.20
3.85%

What the Analysts think about Merck & Co.

Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.

Bulls say / Bears say

Merck’s lead immuno-oncology drug, Keytruda, posted a 9% year-over-year sales increase to just under $8.0 billion in Q2 2025, thanks to expanded approvals for both early-stage and metastatic cancers (Reuters).
The U.S. FDA’s approval of Enflonsia (clesrovimab-cfor) for RSV prevention in infants marks Merck’s first RSV prophylactic effective regardless of weight, strengthening its pediatric vaccine lineup and providing a fresh growth driver for the 2025-2026 RSV season (Reuters).
Merck’s experimental oral PCSK9 inhibitor, enlicitide decanoate, achieved its main goals in two late-phase CORALreef studies by delivering meaningful LDL-C reductions, setting Merck up to enter the cholesterol management market as the first oral PCSK9 therapy (Reuters).
Merck’s Gardasil vaccine sales dropped 55% year-over-year to $1.1 billion in Q2 2025, mainly due to weak demand in China and a halt in shipments, signaling a major challenge for its vaccine division (Reuters).
Investors are worried about the looming loss of Keytruda’s patent protection in 2028, as Keytruda made up almost half of Merck’s 2024 revenue, and there’s uncertainty if new drugs in the pipeline can fully cover the expected decline (Reuters).
Even after cost reduction measures, Merck slightly lowered its 2025 full-year sales forecast to $64.3–$65.3 billion after a 2% drop in Q2 revenue, highlighting continued pressure on revenue growth and dependence on cutting costs (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

Merck & Co. Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Merck & Co. Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRK

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Sept15
Merck & Co.
DividendEx-dividend
Oct7
Merck & Co.
DividendPayment
$0.81Per share
FAQs